Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 16699171
Obreztchikova M, et al. (2006) Distinct signaling functions for Shc isoforms in the heart. J Biol Chem 281, 20197-204 16699171
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S473-p - Akt1 (rat)
Modsite: RPHFPQFsYSASGTA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
Methods used to characterize site in vivo electrophoretic mobility shift, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  fibroblast-heart
Cellular systems studied:  primary cells
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
isoproterenol no change compared to control
thrombin increase
AG1478 thrombin inhibit treatment-induced increase
EGF increase
AG1478 EGF inhibit treatment-induced increase

T203-p - ERK1 (rat)
Modsite: HDHTGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo electrophoretic mobility shift, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  fibroblast-heart
Cellular systems studied:  primary cells
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
thrombin increase
AG1478 thrombin inhibit treatment-induced increase
PP1 thrombin inhibit treatment-induced increase
U0126 thrombin inhibit treatment-induced increase
phorbol_ester increase
PTX thrombin no effect upon treatment-induced increase
AG1478 phorbol_ester inhibit treatment-induced increase
PP1 phorbol_ester no effect upon treatment-induced increase
U0126 phorbol_ester inhibit treatment-induced increase
EGF increase
AG1478 EGF inhibit treatment-induced increase
PP1 EGF no effect upon treatment-induced increase
U0126 EGF inhibit treatment-induced increase
isoproterenol increase
AG1478 isoproterenol inhibit treatment-induced increase
PTX isoproterenol inhibit treatment-induced increase
angiotensin_2 increase
H2O2 increase
Pasteurella_multocida_toxin increase

Y205-p - ERK1 (rat)
Modsite: HTGFLtEyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo electrophoretic mobility shift, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  fibroblast-heart
Cellular systems studied:  primary cells
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
thrombin increase
AG1478 thrombin inhibit treatment-induced increase
PP1 thrombin inhibit treatment-induced increase
U0126 thrombin inhibit treatment-induced increase
phorbol_ester increase
PTX thrombin no effect upon treatment-induced increase
AG1478 phorbol_ester inhibit treatment-induced increase
PP1 phorbol_ester no effect upon treatment-induced increase
U0126 phorbol_ester inhibit treatment-induced increase
EGF increase
AG1478 EGF inhibit treatment-induced increase
PP1 EGF no effect upon treatment-induced increase
U0126 EGF inhibit treatment-induced increase
isoproterenol increase
AG1478 isoproterenol inhibit treatment-induced increase
PTX isoproterenol inhibit treatment-induced increase
angiotensin_2 increase
H2O2 increase
Pasteurella_multocida_toxin increase

T183-p - ERK2 (rat)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo electrophoretic mobility shift, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  fibroblast-heart
Cellular systems studied:  primary cells
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
thrombin increase
AG1478 thrombin inhibit treatment-induced increase
PP1 thrombin inhibit treatment-induced increase
U0126 thrombin inhibit treatment-induced increase
phorbol_ester increase
PTX thrombin no effect upon treatment-induced increase
AG1478 phorbol_ester inhibit treatment-induced increase
PP1 phorbol_ester no effect upon treatment-induced increase
U0126 phorbol_ester inhibit treatment-induced increase
EGF increase
AG1478 EGF inhibit treatment-induced increase
PP1 EGF no effect upon treatment-induced increase
U0126 EGF inhibit treatment-induced increase
isoproterenol increase
AG1478 isoproterenol inhibit treatment-induced increase
PTX isoproterenol inhibit treatment-induced increase
angiotensin_2 increase
H2O2 increase
Pasteurella_multocida_toxin increase

Y185-p - ERK2 (rat)
Modsite: HtGFLtEyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo electrophoretic mobility shift, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  fibroblast-heart
Cellular systems studied:  primary cells
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
thrombin increase
AG1478 thrombin inhibit treatment-induced increase
PP1 thrombin inhibit treatment-induced increase
U0126 thrombin inhibit treatment-induced increase
phorbol_ester increase
PTX thrombin no effect upon treatment-induced increase
AG1478 phorbol_ester inhibit treatment-induced increase
PP1 phorbol_ester no effect upon treatment-induced increase
U0126 phorbol_ester inhibit treatment-induced increase
EGF increase
AG1478 EGF inhibit treatment-induced increase
PP1 EGF no effect upon treatment-induced increase
U0126 EGF inhibit treatment-induced increase
isoproterenol increase
AG1478 isoproterenol inhibit treatment-induced increase
PTX isoproterenol inhibit treatment-induced increase
angiotensin_2 increase
H2O2 increase
Pasteurella_multocida_toxin increase

S36-p - SHC1 (rat)
Modsite: TPPEELPsPSASSLG SwissProt Entrez-Gene
Orthologous residues
SHC1 (human): S36‑p, SHC1 iso2 (human): , SHC1 iso3 (human): , SHC1 iso6 (human): S36‑p, SHC1 iso7 (human): , SHC1 (mouse): S36‑p, SHC1 iso2 (mouse): , SHC1 iso3 (mouse): , SHC1 (rat): S36‑p, SHC1 iso2 (rat):
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
thrombin increase
AG1478 thrombin inhibit treatment-induced increase
PP1 thrombin inhibit treatment-induced increase
U0126 thrombin inhibit treatment-induced increase
phorbol_ester increase
GF109203X phorbol_ester inhibit treatment-induced increase
AG1478 phorbol_ester inhibit treatment-induced increase
PP1 phorbol_ester no effect upon treatment-induced increase
U0126 phorbol_ester inhibit treatment-induced increase
H2O2 increase
EGF increase
AG1478 EGF inhibit treatment-induced increase
PP1 EGF inhibit treatment-induced increase
U0126 EGF inhibit treatment-induced increase
isoproterenol no change compared to control
norepinephrine increase
Pasteurella_multocida_toxin increase
U0126 Pasteurella_multocida_toxin inhibit treatment-induced increase
GF109203X Pasteurella_multocida_toxin inhibit treatment-induced increase

Y349-p - SHC1 (rat)
Modsite: EEPPDHQyyNDFPGK SwissProt Entrez-Gene
Orthologous residues
SHC1 (human): Y349‑p, SHC1 iso2 (human): Y239‑p, SHC1 iso3 (human): Y194‑p, SHC1 iso6 (human): Y349‑p, SHC1 iso7 (human): Y239‑p, SHC1 (mouse): Y349‑p, SHC1 iso2 (mouse): Y239‑p, SHC1 iso3 (mouse): Y194‑p, SHC1 (rat): Y349‑p, SHC1 iso2 (rat): Y239‑p
Characterization
Methods used to characterize site in vivo electrophoretic mobility shift, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  fibroblast-heart
Cellular systems studied:  primary cells
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
isoproterenol no change compared to control
H2O2 increase
thrombin increase
AG1478 thrombin inhibit treatment-induced increase
PP1 thrombin inhibit treatment-induced increase
phorbol_ester increase
AG1478 phorbol_ester inhibit treatment-induced increase
PP1 phorbol_ester inhibit treatment-induced increase
EGF increase
AG1478 EGF inhibit treatment-induced increase
PP1 EGF no effect upon treatment-induced increase

Y350-p - SHC1 (rat)
Modsite: EPPDHQyyNDFPGKE SwissProt Entrez-Gene
Orthologous residues
SHC1 (human): Y350‑p, SHC1 iso2 (human): Y240‑p, SHC1 iso3 (human): Y195‑p, SHC1 iso6 (human): Y350‑p, SHC1 iso7 (human): Y240‑p, SHC1 (mouse): Y350‑p, SHC1 iso2 (mouse): Y240‑p, SHC1 iso3 (mouse): Y195‑p, SHC1 (rat): Y350‑p, SHC1 iso2 (rat): Y240‑p
Characterization
Methods used to characterize site in vivo electrophoretic mobility shift, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  fibroblast-heart
Cellular systems studied:  primary cells
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
isoproterenol no change compared to control
H2O2 increase
thrombin increase
AG1478 thrombin inhibit treatment-induced increase
PP1 thrombin inhibit treatment-induced increase
phorbol_ester increase
AG1478 phorbol_ester inhibit treatment-induced increase
PP1 phorbol_ester inhibit treatment-induced increase
EGF increase
AG1478 EGF inhibit treatment-induced increase
PP1 EGF no effect upon treatment-induced increase

Y423-p - SHC1 (rat)
Modsite: ELFDDPSyVNIQNLD SwissProt Entrez-Gene
Orthologous residues
SHC1 (human): Y427‑p, SHC1 iso2 (human): Y317‑p, SHC1 iso3 (human): Y272‑p, SHC1 iso6 (human): Y428‑p, SHC1 iso7 (human): Y318‑p, SHC1 (mouse): Y423‑p, SHC1 iso2 (mouse): Y313‑p, SHC1 iso3 (mouse): Y268‑p, SHC1 (rat): Y423‑p, SHC1 iso2 (rat): Y313‑p
Characterization
Methods used to characterize site in vivo electrophoretic mobility shift, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  fibroblast-heart
Cellular systems studied:  primary cells
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
thrombin increase
AG1478 thrombin inhibit treatment-induced increase
PP1 thrombin inhibit treatment-induced increase
phorbol_ester increase
AG1478 phorbol_ester inhibit treatment-induced increase
PP1 phorbol_ester inhibit treatment-induced increase
EGF increase
AG1478 EGF inhibit treatment-induced increase
PP1 EGF no effect upon treatment-induced increase

Y239-p - SHC1 iso2 (rat)
Modsite: EELPDHQyyNDFPGK SwissProt Entrez-Gene
Orthologous residues
SHC1 (human): Y349‑p, SHC1 iso2 (human): Y239‑p, SHC1 iso3 (human): Y194‑p, SHC1 iso6 (human): Y349‑p, SHC1 iso7 (human): Y239‑p, SHC1 (mouse): Y349‑p, SHC1 iso2 (mouse): Y239‑p, SHC1 iso3 (mouse): Y194‑p, SHC1 (rat): Y349‑p, SHC1 iso2 (rat): Y239‑p
Characterization
Methods used to characterize site in vivo electrophoretic mobility shift, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  fibroblast-heart
Cellular systems studied:  primary cells
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
thrombin increase
AG1478 thrombin inhibit treatment-induced increase
PP1 thrombin inhibit treatment-induced increase
phorbol_ester increase
AG1478 phorbol_ester inhibit treatment-induced increase
PP1 phorbol_ester inhibit treatment-induced increase
EGF increase
AG1478 EGF inhibit treatment-induced increase
PP1 EGF no effect upon treatment-induced increase
isoproterenol no change compared to control
H2O2 increase

Y240-p - SHC1 iso2 (rat)
Modsite: ELPDHQyyNDFPGKE SwissProt Entrez-Gene
Orthologous residues
SHC1 (human): Y350‑p, SHC1 iso2 (human): Y240‑p, SHC1 iso3 (human): Y195‑p, SHC1 iso6 (human): Y350‑p, SHC1 iso7 (human): Y240‑p, SHC1 (mouse): Y350‑p, SHC1 iso2 (mouse): Y240‑p, SHC1 iso3 (mouse): Y195‑p, SHC1 (rat): Y350‑p, SHC1 iso2 (rat): Y240‑p
Characterization
Methods used to characterize site in vivo electrophoretic mobility shift, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  fibroblast-heart
Cellular systems studied:  primary cells
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
thrombin increase
AG1478 thrombin inhibit treatment-induced increase
PP1 thrombin inhibit treatment-induced increase
phorbol_ester increase
AG1478 phorbol_ester inhibit treatment-induced increase
PP1 phorbol_ester inhibit treatment-induced increase
EGF increase
AG1478 EGF inhibit treatment-induced increase
PP1 EGF no effect upon treatment-induced increase
isoproterenol no change compared to control
H2O2 increase

Y313-p - SHC1 iso2 (rat)
Modsite: ELFDDPSyVNIQNLD SwissProt Entrez-Gene
Orthologous residues
SHC1 (human): Y427‑p, SHC1 iso2 (human): Y317‑p, SHC1 iso3 (human): Y272‑p, SHC1 iso6 (human): Y428‑p, SHC1 iso7 (human): Y318‑p, SHC1 (mouse): Y423‑p, SHC1 iso2 (mouse): Y313‑p, SHC1 iso3 (mouse): Y268‑p, SHC1 (rat): Y423‑p, SHC1 iso2 (rat): Y313‑p
Characterization
Methods used to characterize site in vivo electrophoretic mobility shift, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  fibroblast-heart
Cellular systems studied:  primary cells
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
thrombin increase
AG1478 thrombin inhibit treatment-induced increase
PP1 thrombin inhibit treatment-induced increase
phorbol_ester increase
AG1478 phorbol_ester inhibit treatment-induced increase
PP1 phorbol_ester inhibit treatment-induced increase
EGF increase
AG1478 EGF inhibit treatment-induced increase
PP1 EGF no effect upon treatment-induced increase